New insider activity at Ultragenyx Pharmaceutical ( (RARE) ) has taken place on March 4, 2025.
Director Karah Herdman Parschauer recently sold 2,990 shares of Ultragenyx Pharmaceutical stock, amounting to a total transaction value of $128,223.
Recent Updates on RARE stock
Ultragenyx Pharmaceutical has experienced notable developments recently, with the FDA accepting their Biologics License Application for UX111 AAV gene therapy, granting it Priority Review. This development, alongside strong earnings results, has led to increased price targets from analysts. Canaccord raised their price target due to Ultragenyx’s top- and bottom-line beat in Q4 2024, driven by growth in their Crysvita, Dojolvi, and Evkeeza franchises. Similarly, TD Cowen increased their price target following the company’s solid progress in Q4. Despite these positive developments, Ultragenyx faces financial challenges, reporting a net loss of $569 million for 2024, though they anticipate revenue growth and aim for profitability by 2027.
More about Ultragenyx Pharmaceutical
YTD Price Performance: 4.30%
Average Trading Volume: 846,706
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $3.97B